1. Home
  2. TACH vs CLLS Comparison

TACH vs CLLS Comparison

Compare TACH & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TACH

Titan Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.34

Market Cap

354.7M

Sector

N/A

ML Signal

N/A

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.80

Market Cap

374.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACH
CLLS
Founded
2024
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
354.7M
374.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TACH
CLLS
Price
$10.34
$3.80
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
50.6K
32.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$40.37
Revenue Next Year
N/A
N/A
P/E Ratio
$39.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.03
$1.10
52 Week High
$10.38
$5.48

Technical Indicators

Market Signals
Indicator
TACH
CLLS
Relative Strength Index (RSI) 61.31 45.66
Support Level $10.26 $3.41
Resistance Level $10.38 $4.46
Average True Range (ATR) 0.01 0.17
MACD 0.00 0.01
Stochastic Oscillator 85.71 40.00

Price Performance

Historical Comparison
TACH
CLLS

About TACH Titan Acquisition Corp. Class A Ordinary Shares

Titan Acquisition Corp is a blank check company.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: